GHK-Cu has stronger evidence in dermal and cosmetic applications, including small human studies demonstrating improvements in skin thickness, density, elasticity, and wrinkle reduction after topical application
By combining conventional and complementary therapies, we can help patients manage their symptoms, improve their quality of life, and achieve their goals
In elderly patients specifically, LCAR absorption appears impaired due to decreased active transport, making ALCAR the more effective option in this population
In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
*Research shows that long-term GLP-1 success rates improve when medication is paired with nutrition, fitness, and behavior support